JP Morgan Chase’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $16.6M | Buy |
86,274
+29,684
| +52% | +$5.87M | ﹤0.01% | 2235 |
|
|
2025
Q4 | $10.7M | Buy |
56,590
+16,872
| +42% | +$3.24M | ﹤0.01% | 2612 |
|
|
2025
Q3 | $7.04M | Buy |
39,718
+1,703
| +4% | +$253K | ﹤0.01% | 3049 |
|
|
2025
Q2 | $4.32M | Sell |
38,015
-2,397
| -6% | -$256K | ﹤0.01% | 3288 |
|
|
2025
Q1 | $4.25M | Buy |
40,412
+2,651
| +7% | +$300K | ﹤0.01% | 3296 |
|
|
2024
Q4 | $4.05M | Sell |
37,761
-18,690
| -33% | -$2.11M | ﹤0.01% | 3551 |
|
|
2024
Q3 | $5.65M | Sell |
56,451
-7,321
| -11% | -$737K | ﹤0.01% | 3129 |
|
|
2024
Q2 | $5.37M | Buy |
63,772
+13,766
| +28% | +$1.1M | ﹤0.01% | 2985 |
|
|
2024
Q1 | $3.66M | Sell |
50,006
-12,873
| -20% | -$949K | ﹤0.01% | 3361 |
|
|
2023
Q4 | $4.49M | Buy |
62,879
+2,664
| +4% | +$157K | ﹤0.01% | 3188 |
|
|
2023
Q3 | $3.61M | Buy |
60,215
+24,481
| +69% | +$1.61M | ﹤0.01% | 3079 |
|
|
2023
Q2 | $2.58M | Sell |
35,734
-12,355
| -26% | -$927K | ﹤0.01% | 3348 |
|
|
2023
Q1 | $3.54M | Buy |
48,089
+9,256
| +24% | +$658K | ﹤0.01% | 3088 |
|
|
2022
Q4 | $2.59M | Sell |
38,833
-25,455
| -40% | -$1.66M | ﹤0.01% | 3368 |
|
|
2022
Q3 | $3.45M | Buy |
64,288
+891
| +1% | +$52.4K | ﹤0.01% | 3041 |
|
|
2022
Q2 | $3.53M | Sell |
63,397
-3,220
| -5% | -$183K | ﹤0.01% | 3087 |
|
|
2022
Q1 | $4.67M | Buy |
66,617
+2,620
| +4% | +$190K | ﹤0.01% | 3068 |
|
|
2021
Q4 | $6.17M | Sell |
63,997
-232
| -0.4% | -$21.4K | ﹤0.01% | 2876 |
|
|
2021
Q3 | $5.58M | Sell |
64,229
-27,185
| -30% | -$2.1M | ﹤0.01% | 2944 |
|
|
2021
Q2 | $7.48M | Buy |
91,414
+18,617
| +26% | +$1.55M | ﹤0.01% | 2687 |
|
|
2021
Q1 | $6.92M | Sell |
72,797
-6,265
| -8% | -$592K | ﹤0.01% | 2700 |
|
|
2020
Q4 | $4.91M | Buy |
79,062
+5,837
| +8% | +$333K | ﹤0.01% | 2828 |
|
|
2020
Q3 | $4.38M | Buy |
73,225
+36,627
| +100% | +$2.5M | ﹤0.01% | 2682 |
|
|
2020
Q2 | $2.55M | Sell |
36,598
-3,196
| -8% | -$203K | ﹤0.01% | 2935 |
|
|
2020
Q1 | $1.8M | Sell |
39,794
-116,519
| -75% | -$6.6M | ﹤0.01% | 3048 |
|
|
2019
Q4 | $10.2M | Buy |
156,313
+7,814
| +5% | +$522K | ﹤0.01% | 2098 |
|
|
2019
Q3 | $9.22M | Buy |
148,499
+111,096
| +297% | +$6.97M | ﹤0.01% | 2192 |
|
|
2019
Q2 | $2.66M | Sell |
37,403
-1,572
| -4% | -$116K | ﹤0.01% | 3184 |
|
|
2019
Q1 | $3.06M | Sell |
38,975
-72,568
| -65% | -$5.5M | ﹤0.01% | 3015 |
|
|
2018
Q4 | $9.44M | Buy |
111,543
+63,923
| +134% | +$6.81M | ﹤0.01% | 2059 |
|
|
2018
Q3 | $8.16M | Buy |
47,620
+33,241
| +231% | +$5.01M | ﹤0.01% | 2366 |
|
|
2018
Q2 | $1.86M | Sell |
14,379
-17,893
| -55% | -$2M | ﹤0.01% | 3469 |
|
|
2018
Q1 | $3.33M | Sell |
32,272
-36,885
| -53% | -$3.65M | ﹤0.01% | 2910 |
|
|
2017
Q4 | $5.91M | Buy |
69,157
+44,028
| +175% | +$3.82M | ﹤0.01% | 2549 |
|
|
2017
Q3 | $2.11M | Buy |
25,129
+13,627
| +118% | +$1.08M | ﹤0.01% | 3119 |
|
|
2017
Q2 | $871K | Buy |
11,502
+2,004
| +21% | +$140K | ﹤0.01% | 3498 |
|
|
2017
Q1 | $627K | Buy |
9,498
+7,363
| +345% | +$484K | ﹤0.01% | 3614 |
|
|
2016
Q4 | $135K | Buy |
2,135
+1,393
| +188% | +$87.9K | ﹤0.01% | 4305 |
|
|
2016
Q3 | $47K | Sell |
742
-5,502
| -88% | -$404K | ﹤0.01% | 4051 |
|
|
2016
Q2 | $465K | Buy |
6,244
+5,107
| +449% | +$379K | ﹤0.01% | 3455 |
|
|
2016
Q1 | $76K | Buy |
1,137
+977
| +611% | +$59.4K | ﹤0.01% | 3803 |
|
|
2015
Q4 | $11K | Buy |
+160
| New | +$9.88K | ﹤0.01% | 4191 |
|
|
2015
Q1 | – | Sell |
-28,708
| Closed | -$953K | – | 4182 |
|
|
2014
Q4 | $953K | Buy |
+28,708
| New | +$934K | ﹤0.01% | 3372 |
|
|
2013
Q4 | – | Sell |
-17,603
| Closed | -$476K | – | 4171 |
|
|
2013
Q3 | $476K | Sell |
17,603
-15,005
| -46% | -$422K | ﹤0.01% | 3658 |
|
|
2013
Q2 | $761K | Buy |
+32,608
| New | +$586K | ﹤0.01% | 3414 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
JP Morgan Chase's LGND Position: Q1 2026 in Review
JP Morgan Chase increased its Ligand Pharmaceuticals (LGND) stake by 52% in Q1 2026, buying an estimated $5.87M and bringing the position to 86,274 shares worth $16.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2235.
JP Morgan Chase first reported a position in LGND in Q2 2013 and has held it in 45 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- JP Morgan Chase held 86,274 shares of Ligand Pharmaceuticals worth $16.6M as of Q1 2026.
- JP Morgan Chase bought 29,684 Ligand Pharmaceuticals shares in Q1 2026, an estimated $5.87M.
- Ligand Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2235 holding.
- JP Morgan Chase first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 45 quarters since.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.